Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00722722 · ClinicalTrials.gov registry record · Phase 2
The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00722722: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT00722722 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00722722, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
Patients planning to have kidney transplantation who are sensitized to their donors have high levels of donor specific alloantibodies. High levels of donor specific antibodies put kidney transplant recipients at risk for rejection very early after transplant. This study is trying to determine if the drug bortezomib (Velcade ™) can reduce donor specific alloantibodies to a level that permits kidney transplantation without a high risk for rejection.
Interventions
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2008-06 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00722722
The ClinicalTrials.gov registry entry for NCT00722722 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bortezomib is the first listed.
NCT00722722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00722722 about?
NCT00722722 is a clinical study titled "The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates". Patients planning to have kidney transplantation who are sensitized to their donors have high levels of donor specific alloantibodies. High levels of donor specific antibodies put kidney transplant recipients at risk for rejection very early after transplant. This study is trying to determine if the...
What is the current status of trial NCT00722722?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2008-06. Estimated completion is 2014-04.
What interventions are being tested in trial NCT00722722?
The interventions under investigation include: Bortezomib (DRUG).
Who is sponsoring clinical trial NCT00722722?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.